MoonLake cut to sell at Goldman Sachs on risks to lead asset's approval
Source: SeekingAlpha
2026-01-15 11:23:48 ET
More on MoonLake Immunotherapeutics
- MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
- MoonLake: Ignore The Panic, Catch The Upside
- MoonLake surges as no additional studies are required for lead drug
- Seeking Alpha’s Quant Rating on MoonLake Immunotherapeutics
- Historical earnings data for MoonLake Immunotherapeutics
Read the full article on Seeking Alpha
For further details see:
MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval
MoonLake Immunotherapeutics
NASDAQ: MLTX
MLTX Trading
0.79% G/L:
$17.255 Last:
279,190 Volume:
$17.14 Open:
MLTX Latest News
MLTX Stock Data
$1,003,283,878
28,454,210
3.61%
24
N/A
Biotechnology & Life Sciences
Healthcare
CH
Zug
